###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
ErbB3 is required for ductal morphogenesis in the mouse mammary gland
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER3 </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2</italic>
###xml 153 156 153 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NEU</italic>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The receptor ErbB3/HER3 is often over-expressed in human breast cancers, frequently in conjunction with over-expression of the proto-oncogene ERBB2/HER2/NEU. Although the prognostic/predictive value of ErbB3 expression in breast cancer is unclear, ErbB3 is known to contribute to therapeutic resistance. Understanding ErbB3 functions in the normal mammary gland will help to explain its role in cancer etiology and as a modulator of signaling responses to the mammary oncogene ERBB2.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 109 113 109 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
To investigate the roles of ErbB3 in mouse mammary gland development, we transplanted mammary buds from ErbB3-/- embryos into the cleared mammary fat pads of wild-type immunocompromised mice. Effects on ductal outgrowth were analyzed at 4 weeks, 7 weeks and 20 weeks after transplantation for total ductal outgrowth, branch density, and number and area of terminal end buds. Sections of glands containing terminal end buds were analyzed for number and epithelial area of terminal end buds. Terminal end buds were also analyzed for presence of mitotic figures, apoptotic figures, BrdU incorporation, and expression of E-cadherin, P-cadherin, alpha-smooth muscle actin, and cleaved caspase-3.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 45 49 45 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2</italic>
###xml 139 143 139 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB4</italic>
###xml 289 293 289 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 342 346 342 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 387 391 387 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 703 707 703 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
The mammary ductal trees developed from ErbB3-/- buds only partly filled the mammary fat pad. In contrast to similar experiments with ErbB2-/- mammary buds, this phenotype was maintained through adulthood, pregnancy, and parturition. In addition, and in contrast to similar work with ErbB4-/- mammary buds, lobuloalveolar development of ErbB3-/- transplanted glands was normal. The ErbB3-/- mammary outgrowth defect was associated with a decrease in the size of the terminal end buds, and with increases in branch density, in the number of terminal end buds, and in the number of luminal spaces. Proliferation rates were not affected by the lack of ErbB3, but there was an increase in apoptosis in ErbB3-/- terminal end buds.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
Endogenous ErbB3 regulates morphogenesis of mammary epithelium.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1270 1271 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 224 229 <span type="species:ncbi:9606">human</span>
The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which consists of EGFR, ErbB2, ErbB3, and ErbB4, is important in many normal developmental processes and is often over-expressed or mutated in human cancer (for review, see [1]). Ligand binding stimulates homodimerization and heterodimerization of EGFR family members. The dimerization facilitates cross-phosphorylation of tyrosines within the cytoplasmic domains that become binding sites for downstream effector proteins. The proto-oncogene product ErbB2 is unique in that it does not bind soluble ligands and requires a heterodimer partner for ligand-dependent activation. ErbB3 is also unique because the kinase domain is catalytically inactive, so that ErbB3 also requires a heterodimerization partner for activity. Once activated, ErbB3 is strongly linked to prosurvival signaling through the phosphatidylinositol 3'-kinase (PI3K)/Akt pathway. ErbB3 has six binding sites for the p85 adaptor subunit of PI3K. PI3K catalyzes formation of 3' phosphoinositides that recruit the protein kinase Akt/protein kinase B to the membrane for activation by phosphorylation. The activated Akt is involved in cellular processes including survival, cell growth, and proliferation (for review, see [2]).
###end p 11
###begin p 12
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 300 309 300 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The ErbB2/ErbB3 heterodimer, one of many possible ErbB heterodimer combinations, is important in tumorigenesis [3-6] (for review, see [7]). ErbB3 is a preferred heterodimerization partner for the proto-oncogene ErbB2, and the ErbB2/ErbB3 heterodimer is highly biologically active and pro-tumorigenic in vitro [8]. ErbB2 and ErbB3 are often co-over-expressed in breast, ovarian, colorectal, and bladder cancers [9-13].
###end p 12
###begin p 13
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 778 783 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2</italic>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 977 981 977 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MET </italic>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1104 1106 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1169 1174 <span type="species:ncbi:9606">human</span>
Recent advances in the treatment of cancers driven by ErbB alterations include the use of small molecule tyrosine kinase inhibitors and antagonist antibodies [14]. Surprisingly, ErbB3 signaling is often crucial to the success or failure of ErbB tyrosine kinase inhibitors, despite the lack of intrinsic ErbB3 kinase activity. In breast cancers with amplified ERBB2, ErbB3 augments ErbB2 signaling through strong coupling to survival pathways that complement the signals emanating from ErbB2, thus allowing the cancer cells to escape from inhibition therapy [15]. In all likelihood, ErbB3 signaling will also contribute to resistance to single and dual specificity EGFR and ErbB2 inhibitors (for example, lapatinib) [16], as they come into clinical use for trastuzumab-resistant ERBB2-amplified breast cancer, and to pertuzumab, an antibody inhibitor of ErbB2/ErbB3 heterodimerization [17]. In non-small-cell lung carcinoma (NSCLC) cells with mutated EGFR, amplification of the MET oncogene activates prosurvival ErbB3 signaling, which allows escape from tyrosine kinase inhibition [18] (for review, see [19]). Given these findings, downregulation of ErbB3 signaling in human cancers is critical to successful ErbB-targeted tyrosine kinase inhibitor therapy.
###end p 13
###begin p 14
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 871 873 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 746 751 <span type="species:ncbi:10090">mouse</span>
###xml 969 973 <span type="species:ncbi:10090">mice</span>
The importance of ErbBs in human breast cancer is linked to their importance in normal mammary gland biology. Understanding these normal functions and their regulators will lead to better prognostication and treatment decisions, and to identification of novel therapeutic targets. However, the individual role played by each receptor in mammary gland development has been difficult to determine. This is because the individual receptors and their agonists display complex and overlapping expression patterns, and because the receptors are required for multiple developmental activities, some of which are essential for prenatal viability [20,21]. Both EGFR and ErbB2 are highly expressed and co-localized in all major cell types in the pubescent mouse mammary gland, but at maturity they are differentially localized, with EGFR in the stroma and ErbB2 in the epithelium [20]. ErbB3 and ErbB4 are only expressed at low levels in postpubescent mammary glands from virgin mice, but they are expressed at higher levels during pregnancy and lactation [20,22]. All four of the ErbBs are expressed in the late pregnancy and early lactation glands. This differential expression pattern implies important roles for EGFR and ErbB2 in the developing mammary gland, and for ErbB3 and ErbB4 in the later stages of mammary gland development and differentiation.
###end p 14
###begin p 15
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 804 810 804 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB4 </italic>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 815 819 <span type="species:ncbi:10090">mice</span>
Early studies suggested that only ErbBs EGFR and ErbB2 are important in early postnatal mammary development, because ErbB3 and ErbB4 are expressed at very low levels, and because neuregulins (NRGs), growth factors that bind exclusively to ErbB3 and ErbB4, were difficult to detect at early stages [20]. Nonetheless, there is evidence for ErbB3 or ErbB4 signaling in the pubescent mammary gland. Implantation of Elvax ethylene vinyl acetate (Elvax Ethylene, Dupont, Wilmington, Delaware, USA) slow release pellets containing NRG1, normally expressed during pregnancy, promoted ductal growth and alveologenesis in mammary glands of pubescent mice [23]. Because NRG1 binds ErbB3 and ErbB4 but not EGFR or ErbB2, this suggested that ErbB3 and/or ErbB4 are functional (but not necessarily active) at puberty. ErbB4 null mice, with the essential cardiac function supplied by transgene-driven expression of ErbB4 cDNA exclusively in the heart, survive past birth and are defective in lactation, but undergo normal development at puberty [24]. This indicates that ErbB4 is not essential during pubescent mammary gland development, and implies, by elimination, that ErbB3 is the active receptor in NRG1 implantation experiments.
###end p 15
###begin p 16
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 485 491 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
Attempts to determine the role of ErbB3 in mammary gland development have been impeded by the embryonic lethality caused by ErbB3 gene disruption, which leads to cardiac and neurodevelopmental defects [25]. To determine the roles played by ErbB3 in mammary gland development, we chose to use a loss-of-function approach. Mammary buds isolated from ErbB3 null embryos at day 12.5 were transplanted into the cleared fat pad of prepubescent immunocompromised recipient mice. Transplanted ErbB3 null buds supported growth of an epithelial tree, but the ducts did not penetrate the fat pad to the same extent as ducts from a wild-type bud transplant. Also, the terminal end buds (TEBs) that pilot ductal extension through the mammary fat pad have an increase in apoptotic structures.
###end p 16
###begin title 17
Materials and methods
###end title 17
###begin title 18
Mammary gland transplants
###end title 18
###begin p 19
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 295 300 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 300 304 300 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 446 449 446 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 456 459 456 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 470 474 470 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 741 746 741 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 746 750 746 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 858 862 858 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 865 870 865 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 870 874 870 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 634 639 <span type="species:ncbi:10090">mouse</span>
A null mutation was created at the ErbB3 gene locus by homologous recombination resulting in the deletion of amino acids 73 to 107. This results in embryonic lethality as early as day 13.5 [25]. Embryonic day 12.5 embryos (stage estimated from timed pregnancies) resulting from an intercross of ErbB3+/- heterozygotes in a mixed 129/C57BL6/BalbC or a high C57BL6 strain background were harvested by Caesarean section. Immunoblot analysis of ErbB3+/+, ErbB3+/-, and ErbB3-/- embryos verified dose-dependent expression of ErbB3 (Additional data file 1). Mammary gland transplants were performed as described in [26]. For each recipient mouse, one number four inguinal mammary fat pad was transplanted with a single mammary bud isolated from a ErbB3-/- female, and the contralateral number four inguinal fat pad was transplanted with a mammary bud from an ErbB3+/+ or ErbB3+/- female littermate. The fat pads containing transplants were harvested from virgin hosts at 4, 7, or 20 weeks after transplantation, or the recipients were bred and the glands harvested at 1 day postpartum. The overall take rate for transplanted buds was 74% and was not affected by the genotype of the donor embryo. All animal work was approved by the Yale University Institutional Animal Care and Use Committee and followed internationally recognized guidelines.
###end p 19
###begin title 20
Morphological analysis
###end title 20
###begin p 21
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Whole mount analysis was carried out as described in [23,26]. Four +/+ and four -/- gland whole mounts of outgrowths were analyzed at 4 weeks after transplantation; three +/+, six +/- and five -/- glands 7 weeks after transplantation; one +/+, one +/- and two -/- glands at 20 weeks after transplantation; four +/- and five -/- glands at 1 day postpartum, after the first pregnancy; and one +/+ and one -/- at 1 day postpartum, after the second pregnancy.
###end p 21
###begin p 22
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Histological analysis was performed as described in [26,27]. Five +/+, three +/-, and seven -/- gland outgrowths were analyzed 4 weeks after transplant; three +/+ or +/- and three -/- glands at 7 weeks after transplant; one +/+ and two -/- glands at 20 weeks after transplantation; three +/- and four -/- glands at 1 day postpartum, after the first pregnancy; and two +/+ or +/- and two -/- 1 day postpartum, after the second pregnancy.
###end p 22
###begin p 23
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Measurements of total ductal outgrowth length on whole glands (no half glands) and branch density (whole and half glands) were taken as described in [26], except with the use of ImageJ imaging software (Wayne Rasband, National Institutes of Health, Bethesda, Maryland, USA). Briefly, the total ductal outgrowth in digital images of glands was determined by drawing a line from the one edge of furthest ductal outgrowth to the opposite edge of furthest ductal outgrowth, and measuring the length of that line in arbitrary units. This analysis was done in triplicate for each gland and the average measurement is reported. The branchpoint analysis was done by counting the number of branchpoints within a box of fixed dimensions. The area of TEBs in digital images of carmine alum-stained whole mounted glands was determined by outlining the TEB using the elliptical or freehand selection tool in ImageJ imaging software. The epithelial area of the TEBs in the sections from paraffin-embedded glands were analyzed similarly, but areas of luminal and other vacuolated spaces were subtracted from the outer measurements to give the epithelial area only.
###end p 23
###begin title 24
Immunohistochemistry
###end title 24
###begin p 25
###xml 148 150 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 361 366 <span type="species:ncbi:10090">Mouse</span>
###xml 512 516 <span type="species:ncbi:9925">goat</span>
Immunohistochemistry (IHC) for E-cadherin, P-cadherin, alpha-smooth muscle actin (SMA) were performed as described by Jackson-Fisher and coworkers [26], except a 1:200 dilution of primary antibody was used for SMA IHC. For E-cadherin IHC, seven +/+, four +/-, and 10 -/- glands were analyzed; and for SMA IHC six +/+, four +/-, and 10 -/- glands were analyzed. Mouse IgG was used as a negative control for both E-cadherin and SMA IHC. For P-cadherin IHC, seven +/+, four +/-, and 10 -/- glands were analyzed and goat IgG was used as a negative control.
###end p 25
###begin title 26
BrdU and cleaved caspase 3
###end title 26
###begin p 27
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 180 186 <span type="species:ncbi:9986">rabbit</span>
###xml 607 613 <span type="species:ncbi:9986">rabbit</span>
5-Bromo-2-deoxyuridine (BrdU) analysis (n = 3 +/+, 1 +/-, and 6 -/-) was performed as described previously [26,28]. For cleaved caspase 3 IHC (n = 5 +/+, 3 +/-, and 7 -/- glands), rabbit polyclonal cleaved caspase-3 (Asp175) antibody (Cell Signaling Technology, Danvers, MA, USA) was used. The antigen was unmasked in a low pH citrate buffer under heat and pressure. The antibody was diluted 1:100 in Primary Antibody Diluting Buffer (Biomeda, Foster City, CA, USA), overnight at 4degreesC. Endogenous peroxidases were inactivated with 1% hydrogen peroxide 10 minutes, and a 1:100 diluted biotinylated anti-rabbit secondary antibody solution (Vectastain Elite ABC kit, PK-6101; Vector Laboratories, Burlingame, CA, USA) was added. Peroxidase activity was detected with freshly prepared DAB solution (Biogenex, San Ramon, CA, USA).
###end p 27
###begin title 28
Histological analysis of apoptosis
###end title 28
###begin p 29
In a double-blind analysis, five TEBs on each hematoxylin and eosin (H&E) stained section were scored for total number of nuclei and for the number of apoptotic cells (n = 6 +/+ or +/-, and 7 -/- glands; 25 slides total). Slides were examined using an Axioskop microscope (Carl Zeiss Microimaging, Thornwood, NJ, USA). Mammary bud epithelial cell nuclei and apoptotic cells within a 100 square (1 mm x 1 mm) grid were counted manually on a laboratory counter (Denominator, Woodbury, CT, USA). Five separate mammary buds were counted for one tissue section per slide at 40x. The ratio of apoptotic cells to nuclei was determined.
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 147 151 147 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in utero </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 337 341 337 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 446 450 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 657 662 <span type="species:ncbi:10090">mouse</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
Analysis of ErbB3 function in postnatal development of the mammary gland has been hampered by the embryonic lethality of ErbB3 knockout mice. ErbB3-/- null mice die in utero at day 13.5 or as late as days 16 to 18, depending on the strain background, because of cardiac cushion abnormalities [25]. However, postnatal development of ErbB3-/- epithelium in ErbB3 wild-type stroma can be analyzed by transplantation. Mammary buds from day 12.5 ErbB3-/- embryos were isolated and transplanted into prepubescent immunocompromised recipient mammary fat pads that had been surgically cleared of the endogenous epithelium. The contralateral gland of each recipient mouse was also cleared of epithelium and transplanted with an ErbB3 wild type (+/+) or heterozygous (+/-) mammary bud from a female littermate embryo as a positive control. At various times after transplantation, the transplanted glands were harvested from the recipient mice and the epithelial tree was visualized by carmine alum staining of whole mounted glands.
###end p 31
###begin p 32
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 74 76 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB</italic>
###xml 174 178 174 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 398 400 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 440 444 440 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 508 510 508 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 545 550 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 550 554 550 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 727 732 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 732 736 732 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 821 826 821 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 826 830 826 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 945 950 945 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 950 952 950 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 956 961 956 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 961 965 961 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1025 1030 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1030 1032 1030 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1067 1072 1067 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1072 1076 1072 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 1248 1253 1248 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1253 1255 1253 1255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1290 1295 1290 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1295 1299 1295 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1378 1383 1378 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1383 1387 1383 1387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1f</xref>
###xml 1422 1424 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e</xref>
###xml 1514 1516 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1h</xref>
###xml 1521 1523 1521 1523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e</xref>
###xml 1526 1531 1526 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1531 1533 1531 1533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1650 1652 1650 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1g</xref>
###xml 1657 1659 1657 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e</xref>
###xml 1678 1683 1678 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1683 1687 1683 1687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1806 1808 1806 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1h</xref>
###xml 1813 1815 1813 1815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e</xref>
###xml 1822 1827 1822 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1827 1829 1827 1829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1845 1850 1845 1850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1850 1854 1850 1854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2057 2061 2057 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </italic>
###xml 2065 2069 2065 2069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-/- </italic>
###xml 2092 2096 2092 2096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1g,h</xref>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 1183 1187 <span type="species:ncbi:10090">mice</span>
At 4 weeks after transplantation the epithelial trees resulting from ErbB3+ (+/+ or +/-) transplant had filled a majority of the fat pad (Figures 1a and 2a), whereas the ErbB-/- transplant epithelial trees only filled a small fraction of the glands (Figures 1b and 2a). The total ductal length was measured for each of the paired contralateral gland outgrowths (four pairs). The length of the ErbB3+ outgrowths and the severity of the ErbB3-/- penetration defect varied at 4 weeks (Figure 2a). The mean ErbB3+ outgrowth length was 412; the mean ErbB3-/- outgrowth was 140. At seven weeks after transplantation, most of the ErbB3+ outgrowths (eight glands) had completely filled the fat pad (Figures 1c and 2b), but none of the ErbB3-/- outgrowths (five glands) filled the fat pad (Figures 1d and 2b). The severity of the ErbB3-/- ductal penetration defects varied. At 7 weeks, transplantation yielded two 'paired' glands from mice in which both ErbB3+ and ErbB3-/- transplants were successful. For these pairs only, the mean ErbB3+ outgrowth length was 721; the mean ErbB3-/- outgrowth was 528 (Figure 2b). For all of the glands assayed, including a number of 'unpaired' glands from mice in which only one of the two transplants survived, the mean ErbB3+ outgrowth length was 737; the mean ErbB3-/- outgrowth was 406. This ductal penetration defect persisted in adult nonparous ErbB3-/- glands (two glands; Figures 1f and 2e), and was not rescued by the influence of hormones during pregnancy or lactation (Figure 1h and 2e). ErbB3+ outgrowths (four glands) filled the fat pad and normal alveolar structures were evident at 1 day postpartum (Figures 1g and 2e). Even though the ErbB3-/- outgrowth did not reach the edges of the fat pad, normal alveolar structures were present at 1 day postpartum (Figures 1h and 2e; four ErbB3+ glands and four ErbB3-/- glands). On the histological level, the alveoli were distended, with milk in the lumens and lipid droplets in the cells, suggesting that both the differentiation and secretory pathways are normal in the +/+ and -/- glands (insets, Figure 1g,h). Analysis of lactation after 1 day postpartum is not possible because the epithelial outgrowth from the transplant is not attached to the nipple, so remodeling of the gland to the prepregnancy state occurs quite rapidly.
###end p 32
###begin p 33
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 92 96 92 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 104 108 104 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 117 121 117 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rag1</italic>
###xml 218 222 218 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 260 267 260 267 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a, b) </bold>
###xml 276 283 276 283 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c, d) </bold>
###xml 292 299 292 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e, f) </bold>
###xml 334 341 334 341 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g, h) </bold>
###xml 434 439 <span type="species:ncbi:10090">mouse</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 594 599 <span type="species:ncbi:10090">mouse</span>
Whole mount analysis of ductal morphogenesis in transplanted glands. Mammary buds from ErbB3+/+ or ErbB3+/- and ErbB3-/- day 12.5 embryos were transplanted into contralateral cleared mammary fat pads of 3-week-old Rag1-/- females. The glands were harvested at (a, b) 4 weeks, (c, d) 7 weeks, (e, f) 20 weeks after transplantation, or (g, h) 1 day postpartum. Shown are paired contralateral transplanted glands from the same recipient mouse. The 20-week glands were from a mouse that was mated but did not deliver a litter and was not pregnant at time of sacrifice. The 1 day postpartum (1D PP) mouse was mated about 8 weeks after transplantation and a litter was delivered about 12 weeks after transplantation. The glands were harvested 1D PP. Inserts in panels g and h are hematoxylin and eosin stained sections of +/+ (panel g) and -/- (panel h) paired transplants at 1D PP.
###end p 33
###begin p 34
###xml 164 168 164 168 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 180 184 180 184 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 330 334 330 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 346 350 346 350 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 381 384 381 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e)</bold>
###xml 621 626 <span type="species:ncbi:10090">mouse</span>
Analysis of epithelial outgrowth. Diamonds represent the average end to end length of total ductal outgrowth measured in arbitrary units in a transplanted gland at (a) 4 weeks and (b) 7 weeks for the null and wild-type or heterozygous (Wt/het) donor genotypes. The average numbers of branchpoints within a unit area are shown for (c) 4 weeks and (d) 7 weeks after transplantation. (e) Ductal outgrowths for 20 weeks after transplantation, mid-pregnancy, and 1 day postpartum (1D PP) are shown together. In all panels, solid lines connect the null with the Wt/het pair of contralateral transplants from the same recipient mouse. Dotted lines connect the mean of the outgrowths from contralateral glands in complete null-Wt/het pairs, and the mean lengths are listed at the termini of these lines. Asterisks represent the mean from all recipients of a given genotype, with mean lengths presented in italics in panels b and d.
###end p 34
###begin p 35
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 110 114 110 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB</italic>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c,d</xref>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 240 244 240 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 615 617 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 854 859 854 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 859 863 859 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1023 1025 1023 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1304 1309 1304 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1309 1313 1309 1313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1328 1333 1328 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1333 1335 1333 1335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1403 1408 1403 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1408 1412 1408 1412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1432 1437 1432 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1519 1521 1519 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1596 1598 1596 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1625 1630 1625 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1630 1632 1630 1632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1687 1689 1687 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1713 1718 1713 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1718 1722 1718 1722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1737 1739 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 1807 1809 1807 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 1890 1895 1890 1895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1895 1897 1895 1897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1939 1944 1939 1944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1944 1948 1944 1948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2024 2029 2024 2029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 2029 2031 2029 2031 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2087 2092 2087 2092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 2092 2096 2092 2096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2206 2211 2206 2211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 2211 2213 2211 2213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2255 2260 2255 2260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 2260 2264 2260 2264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
In addition to the ductal penetration defect, there was an increase in the number of branchpoints in the ErbB3-/- outgrowths in comparison to the ErbB+ outgrowths (Figure 2c,d). Likewise, there was an increase in the number of TEBs in ErbB3-/- glands (Figure 3a). TEBs are bulbous structures found at the invasive ends of an advancing ducts, and are major sites of proliferation and apoptosis in the pubescent mammary gland [29]. Normally, TEBs regress once the developing epithelial tree has reached the edge of the fat pad. At 4 weeks after transplantation, several large TEBs are evident in whole mounts of ErbB3+ outgrowths (Figure 3a, top left). however, by 7 weeks after transplantation (Figure 3a, middle left) the TEBs have mainly regressed and they are not present at 20 weeks after transplantation (Figure 3a, bottom left). TEBs are visible in ErbB3-/- glands at 4 weeks (Figure 3a, top right) and at 7 weeks (Figure 3a, middle right). Interestingly, they have regressed by 20 weeks after transplantation (Figure 3a, bottom right), despite the incomplete extension through the fat pad. The number of TEBs visible in both carmine alum stained whole mounted glands (Figure 3b, top left) and across a series of sections from paraffin-embedded whole glands (Figure 3b, bottom right) was greater in ErbB3-/- glands than in ErbB3+ glands. However the epithelial area of the TEBs was smaller for the ErbB3-/- glands than for the ErbB3+ glands. This was observed in both the carmine alum stained whole mounts (Figure 3b, top right) and in the sections from the paraffin-embedded glands (Figure 3b, bottom right). TEBs from ErbB3+ glands were larger in size and epithelial area (Figure 3c, right) than TEBs from ErbB3-/- glands (Figure 3c, left); the corresponding glands are marked with circles in Figure 3b (lower right). In the carmine alum analysis (three pairs), the mean area of the ErbB3+ TEBs was 631 whereas the mean area of the ErbB3-/- TEBs was 221. In an analysis of the paraffin sections, the mean area of the ErbB3+ TEBs (six glands) was 668, whereas the mean area of the ErbB3-/- TEBs (six glands) was 443. In analysis of only the paired paraffin sections (two pairs), the mean area of the ErbB3+ TEBs was 734 whereas the mean area of the ErbB3-/- TEBs was 395.
###end p 35
###begin p 36
###xml 30 34 30 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 584 588 584 588 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 1022 1027 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1027 1031 1027 1031 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1046 1051 1046 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1051 1053 1051 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1548 1552 1548 1552 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 1606 1611 1606 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1611 1613 1611 1613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1710 1715 1710 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1715 1719 1715 1719 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 551 556 <span type="species:ncbi:10090">mouse</span>
###xml 816 820 <span type="species:ncbi:10090">mice</span>
###xml 1236 1241 <span type="species:ncbi:10090">mouse</span>
Whole mount analysis of TEBs. (a) High-magnification TEBs in carmine alum stained whole mounts. Large bulbous TEBs are present at the end of the advancing duct in +/+,+/- glands at 4 weeks after transplantation (top left), but have regressed by 7 weeks (middle left) and 20 weeks (bottom left) after transplantation. The TEBs in the -/- glands are present at 4 weeks (top right), they persist at 7 weeks (middle right), and have regressed by 20 weeks (bottom right). Whole mounts at a given time point are contralateral glands from the same recipient mouse at the same magnification. (b) Number and area of TEBs after transplantation. Shown are the number of TEBs in a carmine alum (CA)-stained whole mount (top left) and the average epithelial area of the TEBs (top right) at 4 weeks after transplantation in three mice with paired contralateral outgrowth; and the number of TEBs (bottom left) and the epithelial area of the TEB in stained paraffin-embedded sections (bottom right) at 4 weeks aftertransplantation in six ErbB3-/- glands and six ErbB3+ glands, two of which are paired contralateral outgrowths. Solid lines connect the paired null and wild-type or heterozygous (wt/het) contralateral transplants from the same recipient mouse. Dotted lines connect the mean of the outgrowths from contralateral glands in the complete null-wt/het pairs, and the means are listed at the termini of these lines. Asterisks represent the mean from all recipients of a given genotype, with means listed in italics. Circles mark the TEBs shown in panel c. (c) Representative TEBs in paraffin-embedded sections. An ErbB3+ TEB (bottom right) in an hematoxylin and eosin stained paraffin-embedded section compared with a ErbB3-/- TEB (bottom left) taken at the same magnification. Both TEBs were near average size for the respective genotype. Circles in panel b, lower right, mark the corresponding diamonds. TEB, terminal end bud.
###end p 36
###begin p 37
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 557 561 557 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b,d</xref>
###xml 826 828 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 944 949 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 949 953 949 953 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 964 969 964 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 969 973 969 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1077 1078 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1109 1114 1109 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1114 1118 1114 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1130 1134 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4e&#8211;i</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4h</xref>
###xml 1229 1231 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4g</xref>
###xml 1330 1335 1330 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1335 1339 1335 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1351 1355 1351 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4j&#8211;n</xref>
###xml 1550 1552 1550 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4l</xref>
###xml 1624 1626 1624 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4m</xref>
###xml 1658 1663 1658 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1663 1667 1663 1667 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1679 1683 1679 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4o&#8211;s</xref>
###xml 1785 1787 1785 1787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4q</xref>
###xml 1817 1819 1817 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4p</xref>
###xml 1899 1900 1899 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1955 1960 1955 1960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1960 1964 1960 1964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2053 2058 2053 2058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 2058 2062 2058 2062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 2074 2078 2074 2078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4t&#8211;w</xref>
###xml 2219 2221 2219 2221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4u</xref>
###xml 2314 2316 2314 2316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4v</xref>
###xml 1920 1924 <span type="species:ncbi:10090">mice</span>
###xml 2036 2040 <span type="species:ncbi:10090">mice</span>
A cross-section of a classical TEB reveals two distinct epithelial cell layers. The outer layer of cap cells at the advancing end of the buds merges into the more distal myoepithelial layer [30,31]. Cap cells are active sites for proliferation in the TEB and the progenitors for the myoepithelial cells that line the duct and the interior body and luminal cells. The second layer encompasses the inner, multilayered body cells that line the lumen and are thought to be major sites of apoptosis in TEBs [32,33]. Both of these cell types are apparent in ErbB3+/+ TEBs at 4 weeks after transplantation (Figure 4a). The single layer of cap (and myoepithelial) cells is marked by expression of SMA and the adhesion molecule P-cadherin (Figure 4b,d), whereas multilayered body cells express the adhesion molecule E-cadherin (Figure 4c) [34,35]. There is a large lumen surrounded by the body cells in each of the consecutive stained sections from the ErbB3+/+ gland. The ErbB3-/- TEBs have the same general organization, but they differ in the type and severity of the defect (Figure 4, bottom four rows). The first ErbB3-/- TEB (Figure 4e-i) has a single layer of cap cells (Figure 4h) and a multilayered body cell compartment (Figure 4g); however, there are large vacuolated spaces between and the cap and body cell layers. The second ErbB3-/- TEB (Figure 4j-n) also has some spaces between the cap and body cell layers, and the lumen is filled with cells. There is an influx of cells that express smooth muscle actin in the body cell compartment (Figure 4l) and do not express E-cadherin like the surrounding body cells (figure 4m). In a more severely defective ErbB3-/- TEB (Figure 4o-s), there are fewer body cells. There is a single layer of cap cells surrounding a large space (Figure 4q), and few body cells (Figure 4p) that surround a small luminal space. Although the three 4-week TEBs in Figure 4 are from different mice, each of these three types of ErbB3-/- TEB defects can be found in the same gland and in glands from different mice. The 7-week ErbB3-/- TEB (Figure 4t-w) is disorganized in that there is a multilayered SMA-positive cap/myoepithelial cell compartment, with large spaces with the layers (Figure 4u). The normally multilayered body cells are a single layer surrounding a small lumen (Figure 4v).
###end p 37
###begin p 38
###xml 58 64 58 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a-d) </bold>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 101 105 101 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 287 307 287 307 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e-i, j-n, and o-s) </bold>
###xml 602 608 602 608 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(t-w) </bold>
###xml 733 738 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 738 742 738 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
Immunohistochemical analysis of a TEB in serial sections. (a-d) TEBs from serial sections of an ErbB3+/+ gland 4 weeks after transplantation (panels a-d) have a typical single layer cap cell/myoepithelial cell outer layer (panels b and d) and a multilayered body cell section (panel c). (e-i, j-n, and o-s) Serial sections of three representative -/- TEBs at 4 weeks after transplantation. The three TEBs vary in the cap cell layer (panels h, l, and q), in the layers in the body cell layer (panels g, m, and d), and in the size of the spaces between the cap and body cell layers (panels i, j, and o). (t-w) The multilayered cap cell compartment has large spaces and the body cell layer is a single layer in the serial section of an ErbB3-/- TEB from a 7-week post-transplantation gland. cc3, cleaved caspase 3; H&E, hematoxylin and eosin; IgG, negative control antibody; E-cad, E-cadherin; P-cad, P-cadherin; SMA, smooth muscle actin; TEB, terminal end bud.
###end p 38
###begin p 39
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 384 388 384 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 447 451 447 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 563 567 563 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 663 668 663 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 668 670 668 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 679 683 679 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1025 1030 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1030 1034 1030 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1128 1133 1128 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1133 1135 1133 1135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1215 1220 1215 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1220 1224 1220 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1302 1307 1302 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 1307 1309 1307 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The TEB is the major site of proliferation and apoptosis in the developing mammary gland. The proximal cap cells are actively proliferating cells, whereas the body cells that line the duct undergo apoptosis to clear the lumen during growth of the duct [32,33]. A decrease in proliferation or an increase in apoptosis could result in the ductal penetration defect associated with ErbB3-/- transplants. Histological analysis of the H&E stained ErbB3-/- TEBs revealed fragmented condensed nuclei suggestive of apoptosis (Figure 5, top right) in comparison with ErbB3+/+ TEBs (Figure 5, top left). Hence, we enumerated apoptotic bodies in fields of H&E sections from ErbB3+ and ErbB3-/- mammary glands. Of the seven null glands analyzed, the mean number of apoptotic bodies was 2.3 (standard deviation [SD] 2.0). Six wild-type or heterozygous glands had a mean of 0.8 apoptotic bodies (SD 0.5). The counts were also compared after normalization to the total number of epithelial nuclei in each sample. Among all glands analyzed, ErbB3-/- TEBs (seven glands) had a mean ratio of apoptotic bodies to nuclei of 0.03 (SD 0.03), whereas ErbB3+ glands (six glands) had a mean ratio of 0.01 (SD 0.01). In the four pairs only, ErbB3-/- TEBs had a mean ratio of apoptotic cells to nuclei of 0.02 (SD 0.01), whereas ErbB3+ glands had a mean ratio of 0.01 (SD 0.01).
###end p 39
###begin p 40
Apoptosis in TEBs. H&E stained TEBs in +/+ transplanted glands (top left) have few apoptotic nuclei and one cleaved caspase 3 positive (brown stain) cell (middle left). H&E stained TEBs in -/- transplanted glands (top right) have numerous apoptotic nuclei and cleaved caspase 3 positive cells (middle right). BrdU-positive cells (brown stain) are present in both the +/+ transplanted glands (bottom left) and in the -/- transplanted glands (bottom right). BrdU, 5-bromo-2-deoxyuridine; cc3, cleaved caspase 3; H&E, hematoxylin and eosin; TEB, terminal end bud.
###end p 40
###begin p 41
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 21 25 21 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 147 152 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 152 156 152 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 249 253 249 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
The area of the ErbB3-/- TEB with the most apoptotic nuclei also displayed an increase in cleaved caspase 3 positive cells (Figure 5). On average, ErbB3+/+ TEBs had 2.15% cleaved caspase 3 positive cells, with a range of 0.4% to 5.4% positive. ErbB3-/- TEBs had an average of 6.3% cleaved caspase 3 positive cells, with a range of 1.6% to 18.5% positive. Overall, then, there was a trend for null TEBs to show more signs of apoptosis, but the differences may not rise to the level of statistical significance.
###end p 41
###begin p 42
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 167 171 167 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
Proliferation was not affected by the loss of ErbB3. Immunohistological analysis of BrdU labeling yielded similar results for ErbB3+ TEBs (29% BrdU positive) and ErbB3-/- TEBs (32% BrdU positive; Figure 5, lower panels).
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 799 804 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 804 808 804 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Deletion of ErbB3 in the epithelium of the mouse mammary gland resulted in reduced ductal outgrowth that was evident at puberty, and endured through adolescence, pregnancy, and early lactation, establishing that ErbB3 is absolutely required in the epithelium during pubescent mammary gland development. This phenotype is more severe than that induced by knockout of any of the three other ErbBs in mammary epithelium, underscoring the importance of ErbB3 in mammary development. The postnatal requirement of ErbB3 in the stroma was not addressed in this study. This ductal outgrowth/penetration phenotype varied in severity. Lobuloalveolar development was not affected in ErbB3-null glands. Lack of epithelial ErbB3 affected the phenotype of TEBs. TEBs were more numerous but smaller in size in the ErbB3-/- outgrowths. Apoptotic cells were more common within the TEBs in the null glands, but there was no apparent change in the proliferative cells.
###end p 44
###begin p 45
###xml 42 44 42 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
In related experiments, Qu and coworkers [36] inhibited ErbB3 expression in the mammary gland by using Cre recombinase to invert a transcriptional suppressor integrated in an intron. Mammary glands, analyzed at 4 weeks and 8 weeks, had lower ductal density, fewer branches, and fewer TEBs. TEB morphology was not discussed, and neither was development at later time points. The limited analysis, the fact that the experimental approach involved reduction, not elimination, of ErbB3 expression, and other technical differences make it difficult to compare that report with the present study directly.
###end p 45
###begin p 46
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
The pubescent epithelial outgrowth/penetration defect we obtained was accompanied by an increase in the branch density in ErbB3-null glands. Mammary branching is modulated by diverse factors, including members of the EGFR family (for review, see [37]). The interaction between the ErbB family and matrix metalloproteinases (MMPs), in particular, is known to be important in branching. The EGFR promotes activation of MMP-2 and MMP-14, which are important for lung branching and morphogenesis [38]. In the mammary gland, MMP-2 is important for ductal elongation whereas MMP-3 promotes side branching [39,40]. Disruption of the MMP network by the lack of ErbB3 could result in decreased ability of the ducts to penetrate the surrounding stroma.
###end p 46
###begin p 47
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 703 707 703 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
Despite the importance of branching, other abnormalities in the ErbB3-null glands are likely also to contribute to the outgrowth/penetration defect. TEBs are epithelial structures found at the end of a growing duct in the pubescent gland and are responsible for growth and penetration of the normal epithelial tree into the surrounding fat pad. TEBs are evident at the tips of the advancing ducts until the edge of the fat pad is reached, at which point they regress. In the ErbB3-null glands there was an increase in the number of TEBs, probably due to the increase in branching and consequently in the number of ducts, but a decrease in the overall size of the TEBs. On a histological level, the ErbB3-/- TEBs had a range of structural abnormalities that could account for their small size (Figure 4). Some of the TEBs were relatively normal in organization, with an outer single layer of cap and myoepithelial cells marked by P-cadherin expression, an inner multilayered body cell compartment marked by E-cadherin expression, and a central cleared luminal space. A majority of the TEBs had some structural defect including large spaces between the cap/myoepithelial cell layer and the body cell layer, and/or filled in luminal spaces. The most severe TEB abnormalities were detected at 7 weeks after transplantation. The cap/myoepithelial cell compartment appeared to become multilayered and invaded or co-inhabited the body cell compartment, which itself was numerically diminished. This could occur through loss of normal compartmentalization boundaries, and even invasion of the inner layers by the outer layer, perhaps accompanying loss of body cells. Dysregulation of the P-cadherin or E-cadherin adhesion systems could account for some of these structural abnormalities, because they are important for maintaining the boundaries as is netrin/neogenin signaling. It is possible that changes in differentiation of progenitor cells alter the balance of these populations.
###end p 47
###begin p 48
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 825 830 825 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 830 832 830 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1035 1040 1035 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
With the information available, the most likely source of the TEB aberrations is an increased rate of apoptosis. A change in the normal balance between proliferation and apoptosis in the TEBs of a pubertal mammary gland would affect the ability of the epithelial tree to fill the fat pad. The proliferative cap cells are typically located at the distal end of the TEB, whereas the apoptotic cells are located in the inner body cell layer surrounding the hollow lumen [32]. The pattern of apoptotic cells in the TEBs suggests that apoptosis is responsible for clearing of the lumen within the growing duct. In the ErbB3-null glands, proliferation was not affected, but apoptosis as detected by cleaved caspase 3 immunohistochemistry and the presence of apoptotic figures in H&E-stained sections was increased in comparison to ErbB3+ glands. ErbB3 has six binding sites for the p85 adaptor subunit of PI3K and is strongly linked to prosurvival signaling through the PI3K/Akt pathway. The uncoupling of ErbB3 from the PI3K/Akt pathway in ErbB3-null outgrowths could result in the increase in apoptosis detected in the TEBs. An increase in apoptosis would explain the large number of cells in the normally cleared luminal space at 4 weeks after transplantation and then the apparent decrease in body cells numbers in TEBs at 7 weeks in ErbB3-null glands.
###end p 48
###begin p 49
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 902 907 <span type="species:ncbi:10090">mouse</span>
The ErbB3-null pubescent mammary gland phenotype might not be predicted based on earlier studies showing only limited expression of ErbB3 in the pubescent gland. However, implantation of the NRG1 in the pubescent mammary gland stimulated epithelial growth [23]. Hence, one of the NRG receptors ErbB3 and/or ErbB4 can function at this stage of mammary development. Because loss of ErbB3 function, but not loss of ErbB4 function, compromised pubescent mammary development, it is likely that ErbB3 was activated by the implanted ligand. However, ErbB3 is devoid of kinase activity and requires a heterodimerization partner for activation. Among the potential heterodimerization partners EGFR, ErbB2, and ErbB4, only EGFR and ErbB2 are required for ductal outgrowth in the pubescent mammary gland. EGFR is expressed in both the epithelium and stroma, but it is only required in the stroma during pubescent mouse mammary gland development [41]. Hence, ErbB2 may be the unique co-receptor, but EGFR and ErbB4 may work redundantly with ErbB3.
###end p 49
###begin p 50
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2</italic>
###xml 282 287 282 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 328 334 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3 </italic>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2</italic>
The epithelial null phenotype for ErbB2 [26] most closely resembles the phenotype for ErbB3 null, consistent with the importance of ErbB2/ErbB3 signaling at pubescence. ErbB2-null mammary buds transplanted into wild-type fat pads develop into ductal tree that grossly resembles the ErbB3-null phenotype. However, in contrast to ErbB3 nulls, the defect was present in the pubescent gland, but was not evident in adult glands or pregnancy. ErbB2-null TEBs also had structural defects in the TEBs, characterized by a decrease in body cell number, an increase in the presence of cap/myoepithelial-like cells in the prelumenal compartment, and the presence of large luminal spaces. The similar requirement for ErbB2 and ErbB3 in the epithelium of the pubescent mammary gland strongly implies that the ErbB2/ErbB3 heterodimer is important in the epithelium at this stage in development.
###end p 50
###begin p 51
###xml 545 547 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
The heterodimerization partner(s) dictates the range of ligands capable of activating ErbB3 in the pubescent mammary gland. Because ErbB2 does not bind soluble ligands, the ErbB2/ErbB3 heterodimer would need to be activated by ligand-bound ErbB3. However, because growth factors in this family are activated by proteolysis, further work will be required to determine the importance of these agonists in pubescent mammary development. Knockout studies have shown that NRG1 isoform alpha is required, but in adult maturation of the mammary gland [28].
###end p 51
###begin p 52
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 427 432 <span type="species:ncbi:10090">mouse</span>
If ErbB3 is heterodimerized with EGFR, then other ligands could be responsible for transactivation of ErbB3. Of the known EGFR ligands, amphiregulin has been shown to be important and upregulated during pubescent mammary gland development [42,43]. With the mammary defects in amphiregulin-knockout mice, EGFR is probably signaling in the epithelium either as a homodimer or heterodimer with ErbB2 and/or ErbB3 in the pubescent mouse mammary gland.
###end p 52
###begin p 53
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
###xml 179 185 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERBB2 </italic>
###xml 811 814 811 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MET</italic>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1217 1219 1217 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 725 733 <span type="species:ncbi:9606">patients</span>
###xml 1048 1053 <span type="species:ncbi:9606">human</span>
ErbB family members are over-expressed because of amplification or have activating mutations in a variety of human cancers. Mutated EGFR has been found in a subset of NSCLCs, and ERBB2 is amplified and over-expressed in up to 30% of human breast cancers, which is associated with a poorer clinical outcome. In both contexts, the ErbBs are validated therapeutic targets. ErbB3 may be quite important in governing the signaling output of the activated ErbBs, initial response to therapies, and in the development of drug resistance. For example, some NSCLC patients with EGFR mutations with a good clinical response to EGFR inhibitors gefitinib or erlotinib initially, but later develop resistance. In one study, half of these patients developed a second activating mutation, whereas the other half had amplified MET, which encodes a receptor tyrosine kinase activated by hepatocyte growth factor [18] (for review, see [19]). The NSCLC tumors escaped tyrosine kinase inhibition because MET activates ErbB3 and the prosurvival PI3K kinase pathway. In human breast cancer cells that over-express ErbB2 and have also developed resistance to tyrosine kinase inhibitor therapy, there is active PI3K/Akt via ErbB3 signaling [15]. In summary, therapies that target ErbB tyrosine kinase activities, kinase inactive ErbB3 and the downstream PI3K/Akt signaling may evade inhibition. A better understanding of ErbB3 in normal mammary gland signaling will reveal the nature of endogenous regulators, and may be beneficial to development of future directed therapies.
###end p 53
###begin title 54
Conclusion
###end title 54
###begin p 55
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 9 13 9 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB3</italic>
###xml 317 321 317 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
The ErbB3-/- mammary outgrowth defect was associated with a decrease in the size of the TEBs, and increases in branch density, in the number of terminal end buds, and in the number of luminal spaces. Proliferation rates were not affected by the lack of ErbB3, but there was a trend toward increased apoptosis in ErbB3-/- TEBs. Hence, endogenous ErbB3 regulates morphogenesis of mammary epithelium, most likely through impact on cell survival and other ErbB3-regulated processes.
###end p 55
###begin title 56
Abbreviations
###end title 56
###begin p 57
BrdU: 5-bromo-2-deoxyuridine; EGFR: epidermal growth factor receptor; H&E: hematoxylin and eosin; IHC: immunohistochemistry; MMP: matrix metalloproteinase; NRG: neuregulin; NSCLC: non-small-cell lung carcinoma; PI3K: phosphatidylinositol 3'-kinase; SD: standard deviation; SMA: alpha-smooth muscle actin; TEB: terminal end bud.
###end p 57
###begin title 58
Competing interests
###end title 58
###begin p 59
The authors declare that they have no competing interests.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
AJ-F, GB, and JB carried out the research. FT and CB conducted histological analysis. JKD provided statistical consult and figure design. AJ-F and DFS participated in the design of the study and drafted the manuscript. DFS conceived the study.
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
Additional file 1
###end title 63
###begin p 64
A pdf document showing expression of ErbB3. Immunoblot of empbryonic day (E)12.5 whole embryo lysates probed with anti-ErbB3 antibody (Santa Cruz Biotechnology SC285, 1:1,000) from wild type (+/+), heterozygote (+/-), and (-/-) embryos showed gene dose-dependent expression of ErbB3. Loading control is glyceraldehyde 3-phosphate dehydrogenase detected by immunoblotting with antibody SC25778.
###end p 64
###begin p 65
Click here for file
###end p 65
###begin title 66
Acknowledgements
###end title 66
###begin p 67
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
The authors are grateful to Sharon Erickson at Genentech and Kuo-Fen Lee at the Salk Institute for the ErbB3 knockout mice; Carol Wehling at the University of Colorado Health Science Center for the cleaved caspase-3 immunohistochemistry protocol; and Frank Jones and Todd Camenisch for help with the ErbB3 mice. This work was supported by PHS grant R01CA45708 from the National Cancer Institute.
###end p 67
###begin article-title 68
EGF-ERBB signalling: towards the systems level
###end article-title 68
###begin article-title 69
###xml 71 76 <span type="species:ncbi:9606">human</span>
The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer
###end article-title 69
###begin article-title 70
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
###end article-title 70
###begin article-title 71
###xml 31 36 <span type="species:ncbi:9606">human</span>
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
###end article-title 71
###begin article-title 72
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
###end article-title 72
###begin article-title 73
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
###end article-title 73
###begin article-title 74
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
###end article-title 74
###begin article-title 75
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
###end article-title 75
###begin article-title 76
Prognostic value of ERBB family mRNA expression in breast carcinomas
###end article-title 76
###begin article-title 77
Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder
###end article-title 77
###begin article-title 78
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
###end article-title 78
###begin article-title 79
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
###end article-title 79
###begin article-title 80
ErbB-3 predicts survival in ovarian cancer
###end article-title 80
###begin article-title 81
Targeting HER proteins in cancer therapy and the role of the non-target HER3
###end article-title 81
###begin article-title 82
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
###end article-title 82
###begin article-title 83
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
###end article-title 83
###begin article-title 84
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
###end article-title 84
###begin article-title 85
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
###end article-title 85
###begin article-title 86
HER3 and mutant EGFR meet MET
###end article-title 86
###begin article-title 87
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland
###end article-title 87
###begin article-title 88
ErbBs in mammary development
###end article-title 88
###begin article-title 89
Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis
###end article-title 89
###begin article-title 90
Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli
###end article-title 90
###begin article-title 91
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality
###end article-title 91
###begin article-title 92
###xml 113 117 <span type="species:ncbi:10090">mice</span>
ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice
###end article-title 92
###begin article-title 93
ErbB2 is required for ductal morphogenesis of the mammary gland
###end article-title 93
###begin article-title 94
###xml 62 77 <span type="species:ncbi:10090">transgenic mice</span>
Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation
###end article-title 94
###begin article-title 95
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland
###end article-title 95
###begin article-title 96
Key stages in mammary gland development: the mammary end bud as a motile organ
###end article-title 96
###begin article-title 97
Postnatal mammary gland morphogenesis
###end article-title 97
###begin article-title 98
Mammary ductal elongation: differentiation of myoepithelium and basal lamina during branching morphogenesis
###end article-title 98
###begin article-title 99
###xml 40 46 <span type="species:ncbi:10090">murine</span>
Apoptosis in the terminal endbud of the murine mammary gland: a mechanism of ductal morphogenesis
###end article-title 99
###begin article-title 100
Illuminating the center: mechanisms regulating lumen formation and maintenance in mammary morphogenesis
###end article-title 100
###begin article-title 101
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
Expression and functional role of E- and P-cadherins in mouse mammary ductal morphogenesis and growth
###end article-title 101
###begin article-title 102
Myoepithelial cell differentiation in the developing mammary gland: progressive acquisition of smooth muscle phenotype
###end article-title 102
###begin article-title 103
Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy
###end article-title 103
###begin article-title 104
Hormonal and local control of mammary branching morphogenesis
###end article-title 104
###begin article-title 105
Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2
###end article-title 105
###begin article-title 106
Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes
###end article-title 106
###begin article-title 107
Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis
###end article-title 107
###begin article-title 108
Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development
###end article-title 108
###begin article-title 109
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland
###end article-title 109
###begin article-title 110
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development
###end article-title 110

